Sanofi (ETR:SNW)
80.68
+0.48 (0.60%)
Sep 19, 2025, 5:35 PM CET
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
€551,871
Profits / Employee
€110,114
Market Cap
97.90B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
Dec 31, 2020 | 99,412 | -997 | -0.99% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Siemens Healthineers AG | 72,000 |
Merck KGaA | 59,020 |
Bayer Aktiengesellschaft | 91,864 |
Fresenius SE & Co. KGaA | 176,486 |
Sartorius Aktiengesellschaft | 13,528 |
Fresenius Medical Care AG | 111,513 |
Fielmann Group AG | 24,363 |
Carl Zeiss Meditec AG | 5,730 |
Sanofi News
- 2 days ago - Irelands pharma sector is world class, but why dont we have a Novo Nordisk to take our success to the next level? - Independent Ireland
- 3 days ago - Sanofi's Brivekimig Shows Efficacy In Biologic-Naïve HS Patients In Phase 2a Study - Nasdaq
- 3 days ago - Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study - Benzinga
- 3 days ago - Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study - GlobeNewsWire
- 5 days ago - How the UK fell out with big pharma - CNBC
- 8 days ago - Britain is ‘a terrible place’ to sell medicines, says drug firm executive - The Guardian
- 9 days ago - Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration - Benzinga
- 9 days ago - Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration - GlobeNewsWire